• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Gastroenterology and Urology Devices Panel Meeting - June 25, 2008

On June 25, 2008, the Gastroenterology and Urology Devices Advisory Panel met to discuss, make recommendations, and vote on a premarket approval application, sponsored by Medical Enterprises, Ltd., for a drug/device combination product designed to prevent recurrence of bladder cancer. Synergo SB-TS 101.1 Device with Mitomycin C is indicated for use for prophylactic treatment of recurrence in patients following endoscopic removal of Ta-T1 and G1-3 superficial transitional cell carcinoma of the bladder (STCCB). Ta-T1 refers to the stage of the tumor, which is a measure of how deep the tumor penetrates into the bladder wall, with Ta and T1 being the most superficial stages for raised bladder tumors. G1-3 refers to the tumor grade, which is a measure of how aggressive the tumor is likely to grow, with G1 being the least aggressive, and G3 the most aggressive. Synergo with Mitomycin C treatment is therefore clinically indicated for STCCB patients of intermediate and high risk.

The panel members voted unanimously to approve with conditions. The conditions are:

  1. The indications for use statement should be amended to state that patients with low risk bladder cancer (Ta, Grade 1, <3 cm, single tumors) should not be treated;
  2. Mandated training should be developed and implemented for clinician users;
  3. A post-approval study as presented by the sponsor should be performed to focus on adverse events in United States subjects for one year; and
  4. The patient guide labeling must be provided to all users.

Contact: Jeffrey Cooper, DVM; Executive Secretary; jeffrey.cooper@fda.hhs.gov

Transcripts may be purchased from:
Free State Court Reporting
1378 Cape St. Claire Road
Annapolis, MD 21409
800-231-TYPE or 301-261-1902
Transcripts or Executive Summaries may be purchased from:
Food and Drug Administration
Freedom of Information Staff (FOI)
5600 Fishers Lane, HFI-35
Rockville, MD 20852
(301) 827-6500 (voice) or (301) 443-1726 (fax)